hp inc buy pt analyst day give us increas confid pc print pois growth
seanergi maritim hold ship buy pt transform pure capes rais price
 maintain buy analyst jame jang full summari
amedica corpor amda hold sale spine busi complet analyst jason mccarthi ph full
landec corpor buy pt salad kit growth expect deceler howev lifecor natur
food opportun expand analyst anthoni vendetti full summari
sino-glob ship america ltd sino buy pt full steam ahead freight logist revenu grow
brainstorm cell inc bcli buy pt nurown al data medic confer analyst carolin
biolinerx ltd blrx buy pt increas stake lead asset analyst jason mccarthi ph full
trovagen inc trov buy pt licens agreement mit watch ovansertib prostat cancer
vistagen inc vtgn buy pt fda grant second fast-track design neuropath
corpor event call maxim salesperson inform
ellex medic laser elx ax cover vendetti ndr ny ceo tom spurl tue oct
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
california restaur tour habt host orang counti ca mon
research frontier inc refr ndr ny ceo joseph harari mon oct
maxim group first annual tmt confer ctrl host chokshi
klee tue dec
cover klee ndr milwauke madison cfo stan sutula tue dec
cover klee ndr chicago cfo stan sutula wed dec
cover diana ndr ny cfo lui massiani mon oct
pois growth print remain excit
ep guidanc ahead estim consensu rais price
target option print remain excit
sustain pc oper profit profit share gain power
sustain print oper profit growth power adjac
market share gain copier graphic see page
ep guidanc ahead estim consensu rais price
target option print remain excit held
annual secur analyst meet octob provid non-gaap
ep guidanc vs consensu estim
note year ago initi ep guidanc vs consensu
time current consensu effect ep increas
project result attribut guidanc initi
consensu lower initi guid tax rate initi guidanc
net benefit due lower net interest expens
remaind due better expect pc print market well on-going
market share gain given strong record meet exceed commit
oper perspect well profit share gain these pc
printer outlin high degre confid meet
exceed initi guidanc provid addit given increas evid
pc print end market stabil continu gain
share without sacrif margin believ assign multipl consist rest
coverag univers warrant rais multipl target
slightli rais ep estim
result price target increas also note
commit return vs commit higher
end rang track return includ
rais dividend dividend yield final also continu believ
signific option valu associ impress progress make
print believ pois gener increment
oper profit per year vs current next underpin
machineri capit intens rate manufactur industri
market share similar hpq printer market share oper margin
similar asml engin moor law semiconductor
click full note
yesterday announc addit three new bank team
bring total new team eight thu far exce
compani target three five new team per year one reason
maintain posit outlook fundament share
share weak sinc result see investor
appar transfer concern taxi medallion loan see
also fed interest rate hikes/net interest margin nim pressur
regard nim pressur manag modest headwind see
mainli expect new bank team help gener
enough core deposit dampen nim pressur two new team
san francisco deposit rate lower new york citi
anoth like off-set nim pressur slower pace expens growth
system import financi institut sifi threshold
rais billion billion therebi unburden certain
introduc ep estim base loan growth
billion deposit growth exceed loan growth nim
provis taxi medallion loan expens growth
produc effici ratio effect tax rate
view sentiment toward share overli neg present due
fear fed rate hike possibl neg press see
price target equat ep estim in-line
best-in-class mid-cap bank price target could view
aggress time-frame regard reason
knowledg follow longer analyst
enorm confid abil ceo depaolo evp eric
howel grow earn strongli manag risk prudent
concern rais nim compress core nim
loan growth outpac deposit growth requir expens
borrow increment averag fund rate exceed increment averag
yield earn asset total deposit due decreas
escrow deposit tend fluctuat quarter quarter thu exacerb
regard nim pressur modest headwind earn
confer call manag guid per quarter nim pressur
deposit growth match loan growth manag said
expect manag confirm guidanc confer
septemb part averag deposit alreadi increas
billion addit manag indic expect less nim
pressur note enter interest rate swap
benefit nim
concern also appar rais new york time articl articl publish
web juli print juli new york time state and/or impli
major major bank trump famili trump
inner circl emphasi michael cohen kushner ivanka trump
director releas entitl signatur bank respond
largest inaccuraci new york time articl juli
challeng variou alleg articl importantli refut overal
mislead narr articl taken new york time articl
probabl immateri increment exist prospect investor could
materi view
credit qualiti strong first quarter two year
taxi medallion loan exposur appear issu
loan portfolio taxi medallion loan credit qualiti remain
excel loan non-accru confer septemb
manag indic alreadi sold taxi medallion
price higher written-down carri valu
maintain price target share current trade ep
estim price target equat ep estim in-line
best-in-class smid-cap bank
reiter buy rate next four quarter expect stock price appreci
price target addit paid first-ev quarterli
dividend repres annual yield view
broaden base investor one dividend-pay stock
click full note
salad kit growth expect deceler howev
lifecor natur food opportun expand
lifecor new multipurpos fill line provid
vial- syringe-fil capac expect begin commerci product
may pend fda approv new drug plan
smart salad kit nearli doubl us retail distribut
week end manag remain focus drive brand
awar gain slot addit sku exist custom
increasingli focus reduc cost food busi
engag identifi implement cost save initi
continu invest year natur food busi
compani launch organ appl cider vinegar plant soup
prepar addit innov
bottom line would continu buyer aug
confer call believ differ revenu mix indic compani trend
right direct strong distribut alreadi place smart salad kit
expect newer adjac product line o-brand oliv oil vinegar
plant pure-pl soup drive growth go forward final expect lifecor
continu gener high-margin sale growth expand sale new custom
commerci product develop pipelin
lifecor expect lifecor gener double-digit revenu growth least
broaden busi expand capabl compani complet
instal new multi-purpos fill line expect go
valid test commerci product target begin
new line use fill commerci quantiti drug product vial
addit fill syring full capac could gener annual
compani expect receiv fda approv new drug plan manufactur
end although revenu rel flat expect growth
remain three quarter especi feb
favor y/i comp due larg revenu shift neg impact
guidanc introduc guidanc revenu
slightli consensu bracket new estim
prior estim also expect ep break-even
slightli posit compar consensu estim
tweak estim due slightli better-than-expect revenu
guidanc well expect tweak revenu
estim respect
compel valuat trade ev/revenu estim
compar peer averag price target base dcf
analysi discount rate perpetu growth rate price target
impli share trade ev/revenu estim still signific
discount industri averag
click full note
licens agreement mit watch ovansertib
trovagen announc compani enter exclus patent
licens agreement mit develop combin therapi includ
polo-lik kinas plk inhibitor anti-androgen view
signific posit trovagen importantli translat
potenti prostat cancer space treatment paradigm
continu shift xtandi zytiga erleada
realli mean view anti-androgren xtandi zytiga
eleada continu move earlier line therapi caveat
use sequenti one fail option iv chemotherapi
ovansertib demonstr synergi pre-clin zytiga rational
patient progress anti-androgen ovansertib combin
could potenti extend time drug thu extend time chemo
necessari
basi preclin work trovagen initi studi zytiga
abirateron anti-androgen /prednison metastat castration-resist
prostat cancer mcrpc patient earli stage data
studi could signific pc space
phase open-label multicent studi evalu onvansertib
combin zytiga abirateron /prednison patient metastat castration-
resist prostat trial enrol mcrpc patient show earli sign
diseas progress demonstr two rise valu abiraterone/
prednison expect evalu proport patient achiev diseas
control week combin treatment follow patient occur everi
progress first metastasi patient treat anti-androgen xtandi/
zytiga cancer broke intraven anti-tubulin chemotherapi
follow high still given first howev xtandi
erleada given high still asymptomat diseas
metastasi overal translat much larger popul shift standard
care given anti-androgen use earlier extend time diseas
progress resist cancer breakthrough still like occur challeng
xtandi erleada zytiga use sequenti due cross-resist
leav option cancer break iv chemotherapi anti-androgen
pre-metastasi set patient begin progress rise
onvansertib top anti-androgen could extend time iv chemo
necessari still earli stage given size anti-androgren market recal
 j/cougar nr pfizer/mediv nr onvansertib could stir
pc space posit data
click full note
 maintain buy pt
sino-glob sino report result core growth segment
freight logist busi increas revenu y/i
rais forward estim expect sino continu win
complementari contract new on-line freight match system
allow revenu margin expans
sino continu expand custom base enter ship
value-ad raw materi coal sulfur wood product contain
result buoy growth freight logist busi continu
transit pure-play logist oper sino-glob report revenu
highest total compani histori revenu rose y/i
mainli due compani execut strategi increas freight logist
busi freight logist account revenu
relat on-line freight match servic includ staf develop cost
led miss bottom line anticip ep
versu report
revis forward estim expect revenu
margin expans sino on-line freight match servic
look revenu increas million million prior
ebitda million million prior ep prior
look revenu increas million million prior ebitda
million million prior ep prior
sino continu broaden custom base util global relationship
sino expand logist busi includ natur resourc
sulfur wood product miner coal transship australia
china addit compani enter joint ventur ningbo far-east
hong kong engag ship agenc manag servic jv
allow sino leverag newli develop infrastructur help build global
network ship agenc believ could expand earn
potenti freight logist busi
on-line platform develop allow revenu margin
expans due sino focu revers logist oper
china compani partnership cosco ship nr
sino help ship teu approxim ton per teu sulfur port
long beach china amount empti contain export china sino
identifi revenu opportun help fill empti contain prefer
cost per teu expect segment continu increas forecast
period chines far east import continu outpac contain
valuat believ sino inflect point view current market
discount price target undeserv price target deriv
year dcf assum perpetu growth rate wacc furthermor
peer group current trade price-to-earnings estim sino
current trade price-to-earnings estim price target base
ep estim industri averag therefor
believ compani current valuat compel reiter buy
rate price target
click full note
 maintain buy
seanergi maritim ship announc success acquir
capes vessel concurr sold two non-cor supramax
vessel
exchang vessel ship pure capes play
 capit market view transact benefici current
sharehold target increas prior
rais price target expect capes vessel valu
appreci much faster end due tight suppli
qualiti capes vessel
reduc estim due less avail ship day relat
deliveri schedul transact vessel howev rais
estim expect greater oper leverag addit
pure-play capes vehicl allow greater earn potenti
transform publicli list pure-play capes compani
ship reach agreement sell two non-cor supramax asset
gladiatorship guardianship gross proce
in-lin vessel estim also note vessel tier tonnag
regul possibl favor tier vessel believ sale done
opportun time vessel schedul deliv new owner
month addit ship agre purchas south korean capes
vessel purchas fund outstand loan remain
two supramax vessel avail cash hand two transact
ship expos capes segment believ offer greatest
upsid within dri bulk sector market upturn newli acquir capes
vessel current charter per day
rais price target expect capes asset valu appreci
end capes asset valu continu move five-year low
supply/demand fundament tighten dri bulk sector expect
capes asset valu appreci therefor base updat fleet profil
rais price target new price target base
multipl forward normal estim prior
capes segment continu firm unseason low rate
environ caus heavi rain brazil late start
chines new year capes rate start strengthen capes spot rate
averag capes rate increas
expect rate expans
oper leverag enhanc transact complet revis estim
base ship updat fleet profil revis estim
expect net revenu prior oper loss
loss ebitda prior new estim
base lower fleet oper day due vessel deliveri schedul
expect net revenu prior oper ep
prior ebitda prior
click full note
increas stake lead asset
biolinerx announc increas stake lead oncolog program
reduc payment biokin privat
sub-licens receipt
term biolinerx paid cash part debt financ
rate interest month repay period
restrict blrx share mileston biokin also includ
biolin greater share lead product
platform molecul oncolog stem cell mobil greater share
compani may favor partner opportun
advanc later stage develop advanc stem
phase genesi trial genesi trial design test g-csf
stem cell mobil hematopoiet stem cell hsc autolog
transplant multipl myeloma part studi lead-in period patient
assess safeti preliminari efficaci announc aug first
singl dose g-csf induc cell patient
apheresi session requir one data safeti robust
enough dmc recommend move directli part placebo control
portion trial expect enrol patient across center patient
receiv five day gcsf treatment dose day
option expand treatment day gcsf day
apheresi collect stem cell perform day addit
session reach goal cells/kg primari endpoint trial
superior singl dose g-csf vs g-csf alon reach
stem cell mobil threshold apheresi session secondari endpoint
includ time engraft neutrophil platelet durabl engraft
safeti data expect
catalyst ahead besid genesi trial also involv sever
phase two trial could report data combat studi
keytruda pancreat cancer expect yield top-lin result octob
esmo confer result addit cohort investig
keytruda chemotherapi tripl expect report could
see interim data on-going combin trial cytarabin
consolid aml biolinerx also recent announc initi phase
trial novel immunotherapi solid tumor data studi
expect
click full note
sale spine busi complet
amedica announc close sale spinal implant franchis
medic privat lead spinal devic retail compani includ
debt assum interest-fre promissori issu amda
certain mileston includ transact
exclus manufactur agreement silicon nitrid spinal product
also assum amedica name -amedica amedica
newco sintx technolog sintx focu contract manufactur
divest spinal franchis gener revenu histor
amedica bottom line spinal franchis high spend low margin
busi addit compound lack complet
spectrum spinal implant compon one supplier
need one surgeri creat difficulti drive sale compani
opt divest spine complementari product also
gain attribut silicon nitrid
view amedica fundament thesi predic revenu growth
spinal franchis divest evalu newco
busi model go forward remain hold rate
silicon nitrid super biomateri implant fusion silicon nitrid
ceram materi attract properti use medic devic may
overcom limit biomateri includ allo-bon metal plastic
silicon nitrid promot bone growth hard strong resist fractur
antibacteri resist wear non-corros imag compat amedica
fda-approv iso-certifi silicon nitrid devic manufactur facil
 compani manufactur silicon nitrid four form solid porou
composit solid porou coat
valu proposit silicon nitrid view anti-infect properti offer
particularli attract valu proposit insur compani infect
common complic spine hip knee implant significantli
increas cost spinal fusion estim place averag cost surgic
site infect occur patient lead expect
cost infect per patient cost increas hip knee
replac cost run high per infect occur
knee hip replac respect lead expect cost
medic -amedica spinal fusion market valu billion
 highli competit marketplac requir signific resourc
captur market share particular full line product essenti get
mani hospit prefer work singl compani entir procedur
medic full line product cervic thorac lumbar fusion
demonstr track record sale growth profit compani product
complement amedica silicon nitrid compon could increas number
procedur use implant addit expect spinal fusion market
supplier regularli releas new product releas
dozen year alon
click full note
fda grant second fast-track design
vistagen announc fda grant track design
non-opioid non-sed treatment neuropath pain
oral nmda antagonist bind glycin site
complet block receptor alreadi track design
neuropath pain np affect approxim million peopl unit
state character steadi burn pin needl
electr shock sensat result abnorm neuron function
trauma nerv viral infect certain medic metabol insult
fast-track design np underlin fda focu
support develop non-opioid altern pain
step preclin data np anim model show dose-
depend anti-nocicept effect similar gabapentin vistagen plan
conduct phase ii trial await trial design detail
conclus view news increment posit vistagen
manag execut plan develop platform therapeut
within space note on-going phase elev trial
mdd expect read data
neuropath pain accord medic literatur neuropath pain preval
popul chronic pain neuropath
natur treatment includ opioid oxycodon hydrocodon anticonvuls
gabapentin pregabalin antidepress ssri snri side effect profil
drug includ addict sedat suicid thought interact
sed effect patient much need indic vistagen conduct
preclin anim studi neuropath pain system deliveri
rat model achiev high brain concentr exceed
half maxim inhibitori concentr nmda receptor glyb site result
studi show dose-depend anti-nocicept effect similar gabapentin
howev without side effect compani plan conduct phase ii trial
nmda receptor modul bind glyb glycine-bind coagonist
site subunit subunit ketamin bind differ
fulli block receptor instead downregul activ
moa allow ketamine-lik efficaci fast onset action without
ketamin psychotomimet side effect safeti issu importantli
oral at-hom medic may ideal long-term use depress and/or
step-down intranas inject approach data small nimh studi
treatment-resist mdd expect elev data adjunct
soc frontlin fail mdd expect repres catalyst
stock posit data emerg
click full note
nurown al data medic confer
brainstorm present northeast amyotroph later sclerosi
neal confer clearwat florida cell gene meet
confer la jolla california confer take
poster neal confer present data
phase trial nurown al data explor microrna chang
neuroprotect scientif workshop take place cell gene
meet compani discuss nurown cell therapi program
view confer opportun compani highlight
nurown data al recal demonstr slow diseas
progress laid foundat on-going phase pivot program
phase trial continu enrol data expect later next year
addit nurown cell design super secret neuron
growth factor potenti util multipl indic expect
brainstorm could announc new initi could also catalyst
stock
poster present microrna chang nurown phase al random
clinic trial relationship neuroprotect innat immun
time pm pm eastern time clearwat florida
locat opal foyer opal sand resort clearwat florida
cell gene meet confer
scientif workshop success strategi design deliveri cell gene
time pacif time la jolla ca
among panel speaker joseph petroziello vice-president scientif corpor
drug develop landscap al nurown clinic advanc outsid
support care al patient essenti therapeut option
radicava approv may multipl therapi includ gene therapi
develop vm biopharma us arm virom nr
develop modul growth factor serum level promot
angiogenesi improv surviv neuron nr
appli antisens platform mrna silenc prevent format mutat
play role certain inherit form al licens biogen
 nr al- pharma privat develop target monoclon
antibodi target misfold protein clinic develop begin
compani phase ab scienc ab pa nr brainstorm
reduc patient declin improv qol treatment studi
click full note
announc compani third plasma center approv
fda third plasma center two import point
focu
first two center transfer biotest biog de nr
part deal compani last year outlin
note biotest us-bas plasma center bought grifol
grf nr work even better instead
access center raw plasma compani
access grifol see
build plasma center foundat addit access grifol
new plasma center essenti first plasma
center keep sop standard oper procedur licens
protocol would requir open addit center
conclus establish new plasma center view smart move
manag new center set foundat build center
thu could provid second plasma sourc view
de-risk also potenti cost-sav event bivigam
model chang factor revenu plasma center previous remov
onward part biotest deal lower earli revenu bivigam
base time commerci increas revenu build
estim year base expect premium price standard ivig market
share factor net effect chang pt
phase trial primari endpoint prevent
seriou bacteri infect sbi bacteri pneumonia osteomyel bacteri
trial enrol patient pidd
zero sbi requir sbi per patient per year per fda
day lost work school day care due infect per subject per year
unschedul visit physician er day per subject per year
dose higher level anti pneumococc antibodi
serotyp assay vs
high anti-rsv antibodi neutral anti-rsv antibodi averag
higher rise specif antibodi assay
grifols/biotest plasma sourc suppli contract
biotest access plasma make august grifol acquir biotest
plasma center grifol center contract
biotest assign grifol theori access
essenti grifol plasma center mean let look math
center produc liter plasma per year high titer
rsv plasma liter per lot lot could produc gram
recal special ivig command higher
price assum vs standard ivig
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
